Chris Adams, CEO of Andarix Pharmaceuticals, will chair a session at the upcoming Target Selection and Drug Design Conference in Boston, Massachusetts. The conference, scheduled for February 25-27, 2025, will bring together industry experts, researchers, and patient groups to explore advanced strategies in radiopharmaceutical drug development.
The conference will focus on critical scientific advances in radiobiological mechanisms, radiation absorption, and targeting strategies. Experts will discuss innovative approaches using small molecules, peptides, nanobodies, antibody fragments, and advanced linker and chelator technologies to improve pharmaceutical development.
Andarix Pharmaceuticals, known for developing personalized cancer therapies, continues to demonstrate leadership in the radiopharmaceutical field. The company's research centers on somatostatin peptide conjugates, which show promise for treating lung, pancreatic, neuroendocrine, and other cancer types. Their approach leverages extensive research demonstrating that somatostatin receptors are highly active in several solid tumor varieties.
By convening leading minds in medicinal chemistry, radiobiology, computational biology, and commercial strategy, the conference represents a significant opportunity to advance understanding of targeted therapeutic approaches. The gathering will provide critical insights into drug discovery, from initial target selection through comprehensive design strategies.
Adams' leadership in chairing a conference session underscores Andarix's commitment to pushing boundaries in cancer treatment research and developing more precise, personalized therapeutic interventions.
